Alopecia - Pipeline Review, H1 2020

January 2020 | 190 pages | ID: A47BD37E02BEN
Global Markets Direct

Abstracts

Alopecia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H1 2020, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 16, 7, 1, 15 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Alopecia - Overview
Alopecia - Therapeutics Development
Alopecia - Therapeutics Assessment
Alopecia - Companies Involved in Therapeutics Development
Alopecia - Drug Profiles
Alopecia - Dormant Projects
Alopecia - Discontinued Products
Alopecia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Alopecia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Alopecia - Pipeline by Aclaris Therapeutics Inc, H1 2020
Alopecia - Pipeline by Addpharma Inc, H1 2020
Alopecia - Pipeline by Allergan Plc, H1 2020
Alopecia - Dormant Projects, H1 2020
Alopecia - Dormant Projects, H1 2020 (Contd..1), H1 2020
Alopecia - Dormant Projects, H1 2020 (Contd..2), H1 2020
Alopecia - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Alopecia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aclaris Therapeutics Inc
Addpharma Inc
Allergan Plc
Almirall SA
AnTolRx Inc
Applied Biology Inc
Berg LLC
BiologicsMD Inc
Bioniz Therapeutics Inc
Bioquark Inc
BirchBioMed Inc
Brickell Biotech Inc
BRIM Biotechnology Inc
Cassiopea SpA
Concert Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Eli Lilly and Co
Energenesis Biomedical Co Ltd
Exicure Inc
Follica Inc
Follicum AB
HCell Inc
Histogen Inc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
Kuhnil Pharmaceutical Co Ltd
Lee's Pharmaceutical Holdings Ltd
Maxinovel Pharmaceuticals
Mirae Cell Bio Co Ltd
Moogene Medi Inc
Nepsone ehf
OliX Pharmaceuticals Inc
Pfizer Inc
Phio Pharmaceuticals Corp
Portola Pharmaceuticals Inc
Quark Pharmaceuticals Inc
RiverTown Therapeutics Inc
Samson Clinical Pty Ltd
Samumed LLC
Suzhou Kintor Pharmaceutical Inc
Suzhou Ribo Life Sciences Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Tigo GmbH
Tritech Biopharmaceuticals Co Ltd